UPDATE: Teva's (TEVA) '302 Capaxone Patent Invalidated by U.S. Patent Office
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
(Updated - September 1, 2016 2:51 PM EDT)
Teva Pharma (NYSE: TEVA) lost a third court ruling against Mylan (NASDAQ: MYL) related to Teva's drug Copaxone. Today's decision by the U.S. Patent and Trademark Office stated that claims 1-12 of the ’302 patent are held unpatentable. Previously two other patents were invalidated.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Analogic (ALOG) CEO Green Resigns; Successor Named
- Finjan Holdings (FNJN) Receives European Patent Related to Adaptive Rule-Based Content Scanners
- Cooper-standard Holdings (CPS) Prelim. Q3 Results Outpace Views
Create E-mail Alert Related CategoriesCorporate News, Hot Corp. News, Litigation
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!